Newsroom | 1416 results

OLDWICK, N.J.--(BUSINESS WIRE)--Outbreaks of the Ebola virus and Andes hantavirus are putting a renewed focus on the insurance implications of rare communicable disease spreads and the need for proactive risk management, according to a new AM Best commentary. The Best’s Commentary, “Insurers Better Prepared For Rare Disease Outbreak Amid Lessons From COVID-19,” notes that health experts have said neither virus poses an immediate global threat nor is expected to spread anywhere near the scale of...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.600% senior notes maturi...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, were published in the New England Journal of Medicine. A five-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compare...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31, 2026, and provided corporate updates. “Arcturus continues to advance its rare disease therapeutics portfolio. We have initiated enrollment of our 12‑week CF Phase 2 study in the first quarter of 2026, earlier...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance(2). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “We're off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer. Our R&D pipeline is advancing on multiple fronts – with positive Phase 3 readouts and encouraging mid-stage results buildin...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website...

MIAMI--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF), in collaboration with the University of Miami Public Health Policy Lab, will cohost a webinar, “Will Equity Prevail? The PABS Annex Negotiations at Their Final Hour,” on Thursday, April 23, 2026 at 10:00 AM EDT, virtually via Zoom. Register here. As WHO Pandemic Agreement negotiations enter a decisive phase ahead of the next Intergovernmental Working Group (IGWG) session, Member States are working to finalize the Pathogen Access and Bene...

AUSTIN, Texas & NEW YORK--(BUSINESS WIRE)--BrainCheck Inc., a cognitive workflow platform, today highlighted the publication of a peer-reviewed longitudinal study conducted at UTHealth Houston that used BrainCheck to track cognitive outcomes in patients hospitalized for COVID-19 over a 36-month period. The study, published in The Journal of Neuropsychiatry and Clinical Neurosciences, represents one of the largest and longest-running evaluations of cognitive outcomes following COVID-19 hospitali...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, a part of Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the Centers for Medicare & Medicaid Services has issued indication-specific Healthcare Common Procedure Coding System (HCPCS) codes for Tyenne® (tocilizumab-aazg) for the treatment of COVID-19. The new codes will be effective for Medicare claims for eligible patients administered Tyenne on April 1, 2026. These new COVID-19 HCPC...

LOS ANGELES--(BUSINESS WIRE)--L’AIDS Healthcare Foundation (AHF) exhorte les gouvernements réunis à Yaoundé, au Cameroun, à l’occasion de la 14e Conférence ministérielle de l’OMC, à garantir le maintien du moratoire de longue date sur certains litiges en matière de propriété intellectuelle, connus sous le nom de « plaintes pour non-violation », en vertu de l’Accord de l’Organisation mondiale du commerce sur les aspects des droits de propriété intellectuelle qui touchent au commerce (ADPIC). Ce...